Repository logo
 

Secondary nucleation of monomers on fibril surface dominates $\alpha$-synuclein aggregation and provides autocatalytic amyloid amplification

Published version
Peer-reviewed

Loading...
Thumbnail Image

Type

Article

Change log

Authors

Gaspar, R 
Buell, AK 
Young, L 
Kaminski, CF 

Abstract

Parkinson’s disease (PD) is characterized by proteinaceous aggregates named Lewy Bodies and Lewy Neurites containing α-synuclein fibrils. The underlying aggregation mechanism of this protein is dominated by a secondary process at mildly acidic pH, as in endosomes and other organelles. This effect manifests as a strong acceleration of the aggregation in the presence of seeds and a weak dependence of the aggregation rate on monomer concentration. The molecular mechanism underlying this process could be nucleation of monomers on fibril surfaces or fibril fragmentation. Here, we aim to distinguish between these mechanisms. The nature of the secondary processes was investigated using differential sedimentation analysis, trap and seed experiments, quartz crystal microbalance experiments and super-resolution microscopy. The results identify secondary nucleation of monomers on the fibril surface as the dominant secondary process leading to rapid generation of new aggregates, while no significant contribution from fragmentation was found. The newly generated oligomeric species quickly elongate to further serve as templates for secondary nucleation and this may have important implications in the spreading of PD.

Description

Keywords

Amyloid, Biocatalysis, Kinetics, Molecular Imaging, Protein Multimerization, Protein Structure, Secondary, Surface Properties, alpha-Synuclein

Journal Title

Quarterly Reviews of Biophysics

Conference Name

Journal ISSN

0033-5835
1469-8994

Volume Title

50

Publisher

Cambridge University Press
Sponsorship
European Research Council (337969)
Biotechnology and Biological Sciences Research Council (BB/H023917/1)
Engineering and Physical Sciences Research Council (EP/H018301/1)
Medical Research Council (MR/K02292X/1)
Medical Research Council (G0902243)
This work was supported by the Swedish Research Council and its Linneaus Centers for Organizing Molecular Matter (E. Sparr and S. Linse), the European Research Council (S. Linse), Nanolund (S. Linse), Multipark (S. Linse and R. Gaspar), the Leverhulme Trust (A. Buell), Magdalene College, Cambridge (A. Buell), the Parkinson’s and Movement Disorder Foundation (A. Buell), EPSRC (C.F. Kaminski), MRC (C.F. Kaminski) and Wellcome Trust UK (C.F. Kaminski).